Table 1.

Availability of evidence and panellists’ decisions supporting the use of FDG PET in the diagnostic work-up of the main forms of parkinsonism

PICO question	Relative availability of evidence	Panellists’ recommendations	Main reasons for final decision
12 (PD-related decline)	Very low/lacking	Yes	Sensitive to cortical involvement before cognitive deficits appear
13 (PSP)	Very low/lacking	Yes	Presence of typical hypometabolic patterns
15 (CBS)	Fair	Yes	Presence of typical hypometabolism

Delphi decisions for the other PICO questions of the EANM/EAN initiative led to supporting FDG PET in all clinical scenarios [1] with the exception of preclinical cases [9] and of amyotrophic lateral sclerosis and Huntington’s disease [10]